Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engager

24 Jul 2025

Abstract excerpt

T cell engagement for CD19+ B cell malignancies following a single dose by expressing a transgene encoding a bispecific diabody termed GP101. Here we describe the selection and development of a clinical lead construct, VNX-101, with enhanced safety and efficacy features. A single dose of the virus was effective at eliminating B cell malignancies in humanized mouse xenograft models. We observed a linear...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Cytomegalovirus and herpesvirus research
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40799205
DOI: 10.1016/j.omtm.2025.101541

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engagerPMID 40799205Read ↗

In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignanciesSemantic proximity Read ↗

Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAbSemantic proximity Read ↗

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys.Semantic proximity Read ↗

Human AdV-20-42-42, a Promising Novel Adenoviral Vector for Gene Therapy and Vaccine Product DevelopmentSemantic proximity Read ↗

Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responsesSemantic proximity Read ↗

In vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligandSemantic proximity Read ↗

Engineered AAV9 as <i>in vivo</i> gene delivery platform for the selective transduction of TME cell subsetsSemantic proximity Read ↗

Recent Advancements in AAV-Vectored Immunoprophylaxis in the Nonhuman Primate ModelSemantic proximity Read ↗

Safe Redosable Low-Immunogenic In Vivo CAR-T Therapy for B Cell Malignancies and Solid TumorsSemantic proximity Read ↗

The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8 <sup>+</sup> T cell activity and synergizes with immune check-point inhibitorsSemantic proximity Read ↗

Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2Semantic proximity Read ↗

Single injection of modified self-amplifying RNA encoding a CD19 bispecific T cell engager mediates long-term malignant B cell clearanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.